Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on OncoZenge’s SEK33.3m rights issue, which is intended to strengthen the balance sheet and provide funding for the continued execution of the pivotal Phase III BEAM-Pain trial and subsequent MAA preparations.</li><li>While the issue is meaningfully dilutive for non-participating shareholders, we view the it as appropriate given the company’s transition into full clinical execution and towards potential European commercialization.</li></ul>

Redeye comments on OncoZenge’s SEK33.3m rights issue, which is intended to strengthen the balance sheet and provide funding for the continued execution of the pivotal Phase III BEAM-Pain trial and subsequent MAA preparations.While the issue is meaningfully dilutive for non-participating shareholders, we view the it as appropriate given the company’s transition into full clinical execution and towards potential European commercialization.

OncoZenge: SEK33.3m Rights issue announced

<ul><li>Redeye comments on OncoZenge’s announcement that the first patient has been enrolled in the pivotal Phase III BEAM-Pain trial of BupiZenge.</li><li>We view this as a major operational milestone, marking the company's successful transition from regulatory preparation to clinical execution and bringing BupiZenge another important step closer to potential market approval in Europe.</li></ul>

Redeye comments on OncoZenge’s announcement that the first patient has been enrolled in the pivotal Phase III BEAM-Pain trial of BupiZenge.We view this as a major operational milestone, marking the company's successful transition from regulatory preparation to clinical execution and bringing BupiZenge another important step closer to potential market approval in Europe.

OncoZenge: First patient enrolled in Pivotal Phase III Study

<ul><li>Redeye provides a research update following the Q1 report published by OncoZenge earlier today.</li><li>The report was largely in line with our expectations, aside from a deviation in the cash flow metrics stemming from a negative change in working capital.</li><li>Importantly, in correlation with the report, the company announced that the CTA for the pivotal Phase III study has now received final approval, enabling study initiation.</li></ul>

Redeye provides a research update following the Q1 report published by OncoZenge earlier today.The report was largely in line with our expectations, aside from a deviation in the cash flow metrics stemming from a negative change in working capital.Importantly, in correlation with the report, the company announced that the CTA for the pivotal Phase III study has now received final approval, enabling study initiation.

OncoZenge (Q1 Review): Final CTA approval received, initiating pivotal study

<ul><li>Redeye leaves a comment following OncoZenge’s announcement of a SEK2m bridge financing from major shareholder Linc, aimed at supporting the company through the final stage of its European CTA review.</li><li>While the delayed formal approval extends the regulatory timeline somewhat, we are encouraged to see that OncoZenge has acted swiftly to secure short-term liquidity and maintain full momentum in its preparations for the upcoming pivotal Phase III trial of BupiZenge.</li></ul>

Redeye leaves a comment following OncoZenge’s announcement of a SEK2m bridge financing from major shareholder Linc, aimed at supporting the company through the final stage of its European CTA review.While the delayed formal approval extends the regulatory timeline somewhat, we are encouraged to see that OncoZenge has acted swiftly to secure short-term liquidity and maintain full momentum in its preparations for the upcoming pivotal Phase III trial of BupiZenge.

OncoZenge: SEK2m bridge loan ahead of potential CTA approval

<ul><li>Redeye leaves a comment following OncoZenge’s announcement of conditional acceptance of its Clinical Trial Application (CTA) for the pivotal Phase III study of BupiZenge in Europe.</li><li>We are encouraged to see that the company has successfully addressed regulatory questions and progressed the application to near-final approval, marking an important step as OncoZenge transitions from preparation to execution of its registrational trial.</li></ul>

Redeye leaves a comment following OncoZenge’s announcement of conditional acceptance of its Clinical Trial Application (CTA) for the pivotal Phase III study of BupiZenge in Europe.We are encouraged to see that the company has successfully addressed regulatory questions and progressed the application to near-final approval, marking an important step as OncoZenge transitions from preparation to execution of its registrational trial.

OncoZenge: Conditional acceptance for Phase III trial

Sweden

OncoZenge AB (publ), a pharmaceutical company, engages in the a development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oncozenge (ONCOZ SF)

OncoZenge: SEK33.3m Rights issue announced

Redeye comments on OncoZenge’s SEK33.3m rights issue, which is intended to strengthen the balance sheet and provide funding for the continued...

Redeye

OncoZenge: First patient enrolled in Pivotal Phase III Study

Redeye comments on OncoZenge’s announcement that the first patient has been enrolled in the pivotal Phase III BEAM-Pain trial of BupiZenge. We...

Redeye

OncoZenge (Q1 Review): Final CTA approval received, initiating pivotal study

Redeye provides a research update following the Q1 report published by OncoZenge earlier today. The report was largely in line with our...

Redeye

OncoZenge: SEK2m bridge loan ahead of potential CTA approval

Redeye leaves a comment following OncoZenge’s announcement of a SEK2m bridge financing from major shareholder Linc, aimed at supporting the...

Redeye

OncoZenge: Conditional acceptance for Phase III trial

Redeye leaves a comment following OncoZenge’s announcement of conditional acceptance of its Clinical Trial Application (CTA) for the pivotal Phase...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)